Skip to content

Pharvaris

US · PHVS #2729 by market cap Listed 2021
31.28 -0.38 -1.20%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:01

Valuation each multiple against its own 5-year range

P/B ratio 8.09 Expensive vs history 93rd percentile
5-year average 4.04 · #442 of 514 in Biotechnology
P/E ratio -11.25 Cheap vs history 10th percentile
5-year average -7.49 · forward -10.42
P/S ratio --
5-year average 0.00 · forward 203.65

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Pharvaris (PHVS) 2.21B -10.60 7.62 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value36.43 Economic moatNone UncertaintyVery High

Trading 16.5% below Morningstar's fair value estimate.

Fair value

Pharvaris NV is assigned a 3-star quantitative star rating, reflecting our opinion that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 8% discount to our quantitative fair value estimate of $36.43 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

We need more explanatory data to elaborate on this stock's star rating. We strive to explain the factors driving every rating we assign; however, this is not yet possible for a small fraction of our coverage universe.

Economic moat

This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 20:01:10 · For reference only, not investment advice and not tailored to your situation.

Pharvaris discussion 0 comments

Add a comment